Nemes Laszlo/iStock via Getty Images New phase 1a data showed that Nurix Therapeutics' ( NASDAQ: NRIX ) NX-5948, a BTK degrader for B-cell malignancies, had an objective response rate of objective response rate of 69.2% in heavily pretreated chronic lymphocytic leukemia patients. The participants in the cohort that reported had a median of four previous lines of therapy.
Among efficacy evaluable patients, responses were seen as early as the first scan -- 8 weeks -- and many patients saw the response increase the longer they were on treatment. The company intends to launch a pivotal trial program for the candidate in 2025. More on Nurix Therapeutics Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies Nurix Therapeutics files for mixed shelf securities offering Seeking Alpha’s Quant Rating on Nurix Therapeutics Historical earnings data for Nurix Therapeutics.